Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly results beat expectations, with raised full-year guidance and a larger AI-compute backlog drawing attention. Bulls say customer prepayments and contract-backed financing address funding concerns, while bears remain focused on heavy debt, interest costs, and capital spending; the stocks reaction has been volatile.

CAPR discussion is dominated by the FDAs scheduled Nov. 22 decision on deramiocel for Duchenne muscular dystrophy; many traders read the CEOs upbeat conference-call remarks and launch preparations as encouraging, while others stress that approval is uncertain given the FDA review and prior advisory-panel concerns. The scope of any cardiac data in the initial label is also a point of debate.

Netlists quarterly results and outlook are drawing attention, with traders focused on improved profitability and margins, Samsung licensing revenue, and expected recurring Micron royalties. Many are bullish on the stronger financial position and growth prospects, while others question the decline in product sales and the lack of a confirmed SK hynix deal or Nasdaq uplisting update; speculation about an Hynix agreement remains unconfirmed.

Rigettis Q3 results missed expectations, intensifying concerns about limited revenue, ongoing losses, and a high valuation; bearish traders see a weak commercial business, while bulls point to advances in its quantum hardware and long-term potential. The debate centers on whether technical progress and government support can eventually translate into meaningful customer demand.

NVDA is under pressure as traders react to scrutiny of CEO Jensen Huang over an alleged relationship with a China-linked executive and concerns about possible export-control and disclosure issues; the allegations remain unproven. The community is split between fears of leadership or regulatory fallout and buyers who see the selloff as overdone given AI-chip demand and upcoming earnings.

LightPaths fiscal first-quarter results are drawing attention after revenue came in below expectations, with management pointing to supply-chain delays. Traders are split between concern about execution and the near-term revenue miss, and optimism about the growing backlog, higher margins and expected improvement in supply availability.

Kuras Q3 results and earnings call are drawing attention, with traders highlighting rising KOMZIFTI prescriptions and patient starts alongside an EPS beat. The reaction is broadly upbeat, though discussion also touches on competitive pressure from J&J and a possible stock offering.

Amprius quarterly results are driving attention: revenue growth and a higher full-year outlook were offset by an EPS miss and weaker-than-expected EBITDA guidance, prompting a sharp selloff. Bulls argue the earnings miss was small and emphasize growth and improving margins, while bears point to continued losses and profitability concerns.

NextNavs Q3 report has brought earnings and volatility back into focus, but the dominant debate remains the pending FCC rulemaking on its 900 MHz spectrum and SpaceXs support for its proposed use. Bulls view the spectrum as a valuable strategic asset and speculate about buyers, while bears point to unresolved regulatory approval and repeated delays.

Costcos announced special cash dividend and renewed share-repurchase program are driving attention, with traders mostly welcoming the large payout and discussing eligibility and whether it could support the shares. Some also speculate about short covering, but that remains unconfirmed.